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We identiﬁed 37 hematopoietic cell transplantation recipients with human herpesvirus 6 (HHV-6) central
nervous system dysfunction and tested donor-recipient pairs for chromosomally integrated HHV-6 (ciHHV-6).
One patient had ciHHV-6A with possible HHV-6A reactivation and encephalitis. There was no ciHHV-6
enrichment in this group, but larger studies are needed to determine if patients with ciHHV-6 are at
increased risk for HHV-6eassociated diseases or other complications.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Human herpesvirus 6 (HHV-6) has a unique ability to
integrate into chromosomal telomeres of infected cells [1].
When this occurs in germ cells, Mendelian inheritance results
in offspring with chromosomally integrated (ci) HHV-6 in
every nucleated cell. This condition is present in w1% of
people [1], can be the source of viral reactivation [2,3], and has
been implicated in HHV-6 central nervous system (CNS) dis-
ease [4,5]. To explore whether patients with ciHHV-6 have
increased risk for HHV-6eassociated disease, we tested the
prevalence of ciHHV-6 in allogeneic hematopoietic cell
transplantation (HCT) recipientswithHHV-6CNSdysfunction.
We identiﬁed 37 allogeneic HCT recipients at our center
with HHV-6 CNS dysfunction as previously described [6]. We
tested archived samples from donor-recipient pairs for
ciHHV-6 using a novel method to detect HHV-6 and human
ribonuclease P (RPP30, a reference gene for cell count) DNA
by droplet digital PCR (Figure 1) [7]. CiHHV-6 was ruled out if
the ratio of HHV-6 DNA to cell genome equivalents (2 RPP30/
cell) fell outside the range of 1  .07.
CiHHV-6 species A was detected in 1 pre-HCT patient
sample (prevalence 2.7%; 95% conﬁdence interval, .07% to
14.5%) from a 53-year-old man who developed ﬁndings
consistent with HHV-6 encephalitis after a myeloablative
matched, related donor HCT. He initially developed halluci-
nations and agitation on day 11 after HCT, 1 day after starting
methylprednisolone 2 mg/kg/day for skin rash. Cerebrospi-
nal ﬂuid (CSF) on day þ12 had 2 lymphocytes, 4 red blood
cells, and protein 43 mg/dL. Bacterial, mycobacterial, anddgments on page 372.
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14.09.015fungal stains and cultures were negative, as was PCR for
other herpesviruses. Semiquantitative PCR for HHV-6 DNA
was positive with 2500 copies/mL. The patient was started
on foscarnet 90 mg/kg i.v every 12 hours on day þ14 for
HHV-6 encephalitis.
The patient had initial improvement in mental status
followed by progressive encephalopathy. He engrafted on
day þ17 and was weaned off steroids by dayþ23. Repeat CSF
testing on day þ26 had 2 lymphocytes, 54 red blood cells,
and 2500 copies/mL HHV-6 DNA by semiquantitative PCR.
Additional testing as above was negative. Foscarnet was
discontinued on day þ29 due to acute kidney injury.
Chimerism and ﬂow cytometry studies of bone marrow and
blood on dayþ29 were of donor origin, and PCR for HHV-6 in
bone marrow was negative at that time. Brain magnetic
resonance imaging was negative on day þ33. The patient
developed hypoxia on dayþ38 attributed to aspiration in the
setting of obtundation and died on day þ40 because of
progressive pulmonary disease. An autopsy specimen
revealed possible increased brain microglia and perivascular
lymphocyte cufﬁng, as well as scattered focal hippocampal
neuronal dropout; although nonspeciﬁc, this could be
consistent with viral encephalitis.
Retrospective testing of multiple archived serum samples
with droplet digital PCR detected HHV-6 DNA with
decreasing HHV-6/cellular DNA ratios of .5 to .02 (days 5
through 39). This could be consistent with allograft
replacement of recipient ciHHV-6 hematopoietic cells or
treatment of HHV-6 reactivation with foscarnet. Sanger
sequencing of a 900 base pair region of the HHV-6 envelope
glycoprotein B gene in a pre-HCT cell sample and post-HCT
serum sample (day þ39) revealed complete homology but
divergence from 14 other strains [8] (Figure 2). A fresh-
frozen brain section of the inferior temporal lobe had an
HHV-6/cellular DNA ratio of 1.0, consistent with ciHHV-6 but
without evidence of additional HHV-6 replication. Testing of
formalin-ﬁxed, parafﬁn-embedded samples from the medial
temporal lobes (the predominant site of HHV-6 CNS disease)
Figure 1. Flow diagram for chromosomally integrated HHV-6 testing. Archived pre-HCT patient and donor beta-lymphoblastoid cell lines were the primary source for
ciHHV-6 testing. When unavailable, other appropriate specimens (serum or bone marrow) were used as surrogates. *Surrogate for donor sample in cases that were
missing pre-HCT donor sample. These were obtained after engraftment. yOne patient had a HHV-6/cellular DNA ratio signiﬁcantly >1, making it impossible to rule out
ciHHV-6 coupled with reactivation. HCT, hematopoietic cell transplantation; HHV-6, human herpesvirus 6; CNS, central nervous system; B-lymphoblastoid, beta-
lymphoblastoid; ciHHV-6, chromosomally integrated HHV-6.
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RNA testing and viral culture could not be performed on
archived specimens.
This is the ﬁrst epidemiologic study of the prevalence of
ciHHV-6 in patients with HHV-6-associated CNS dysfunction.
Convincing evidence of HHV-6 reactivation and pathoge-
nicity from ciHHV-6 cell lines is well-described [2-5]. We did
not identify a clear overrepresentation of ciHHV-6 in this
cohort of 37 patients compared with population-based
studies [1], but the conﬁdence interval was wide and sug-
gests an incidence as high as 14.5%. We also describe the ﬁrst
case of a patient with ciHHV-6A and HHV-6A reactivation as
a possible cause of post-HCT encephalitis.Hector-2control
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Figure 2. Phylogenetic analysis of HHV-6A glycoprotein B (gB) gene sequences
from pre and post-HCT samples of the described patient with ciHHV-6A
compared with ciHHV-6A from 4 patients at our center, the Hector-2 cell
line (Bioworld Consulting Laboratories, Mt. Airy, MD), and 9 published se-
quences [8]. This ﬁgure demonstrates that the sequence of anw900 base pair
region of the HHV-6A gB gene in the discussed patient’s pre-HCT beta-lym-
phoblastoid cell line and post-HCT (day þ39) serum sample were identical and
diverged from 14 other available sequences. Bar indicates number of nucleo-
tide changes per 100 sites. The gB gene sequences of 9 HHV-6A primary or
laboratory-adapted isolates were obtained from Dr Henri Agut (Paris, France),
and the geographical origins were as follows: GS, United States; U1102,
Uganda; SIE, Côte d’Ivoire; TAN, Congo; and 1120, E540_132, 1116, 719
and, p523, France. Nucleotide sequences were submitted to GenBank and
assigned the following accession numbers: Hector-2control, KM592979;
Pre-HCT_B-lymphoblastoid_cells, KM592980; Post-HCT_serum, KM592981;
UWciHHV6_1, KM592982; UWciHHV6_2, KM592983; UWciHHV6_3,
KM592984; UWciHHV6_4, KM592985. The tree was constructed from the
comparison of gB gene nucleotide sequences using the free Phylogeny.fr
webservice, available at http://www.phylogeny.fr/version2_cgi/index.cgi.Although HHV-6A DNA detected in post-HCT samples
may have represented cells with ciHHV-6A rather than active
replication, and alternative causes of encephalitis were
possible, we think the ﬁndings are best explained by HHV-6A
reactivation. De novo HHV-6 infection was unlikely given
sequence homology between pre and post-HCT HHV-6
strains. Recipient hematopoietic cells with ciHHV-6A would
be an unlikely source of persistent HHV-6A DNA in serum or
CSF samples after a myeloablative HCT, especially given ev-
idence of full donor chimerism and absence of HHV-6 DNA
detection in the day þ29 bone marrow biopsy. Unfortu-
nately, RNA testing and viral culture of saved specimens were
not possible because of prior processing and extended
storage.
In conclusion, we did not ﬁnd evidence of ciHHV-6
enrichment in a cohort of HCT patients with HHV-6 CNS
dysfunction compared with the general population, but
larger studies are needed to comprehensively determine the
true incidence and prevalence of reactivation in high-risk
patients. Our ﬁndings begin to address the call to reevalu-
ate transplantation practices in the setting of ciHHV-6 [9]
and underscore the need for large, multicenter collabora-
tions to determine the impact of ciHHV-6 on patient
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Whether the number of chemotherapy cycles required to obtain a ﬁrst morphological remission affects
prognosis of patients with acute myeloid leukemia (AML) remains controversial. To clarify how achievement
of early remission might inﬂuence outcome of allogeneic hematopoietic cell transplantation (HCT), we
studied 220 consecutive adults with AML in ﬁrst morphological remission who underwent transplantation
after myeloablative or nonmyeloablative conditioning to investigate how the number of standard- or high-
dose induction courses required to achieve remission impacted post-HCT outcome. Three-year estimates of
overall survival were 65% (95% conﬁdence interval [CI] 56% to 73%), 56% (95% CI, 43% to 67%), and 23% (95% CI,
6% to 46%) for patients requiring 1 course, 2 courses, or >2 courses of induction therapy; corresponding
relapse estimates were 24% (95% CI, 17% to 31%), 43% (95% CI, 31% to 55%), and 58% (95% CI, 30% to 78%),
respectively. After covariate adjustment (minimal residual disease status, conditioning, age, cytogenetic
disease risk, type of consolidation chemotherapy, pre-HCT karyotype, and pre-HCT peripheral blood count
recovery), the hazard ratios for 2 or >2 induction courses versus 1 induction were 1.16 (95% CI, .73 to 1.85,
P ¼ .53) and 2.63 (95% CI, 1.24 to 5.57, P ¼ .011) for overall mortality, and 2.10 (95% CI, 1.27 to 3.48, P ¼ .004)
and 3.32 (95% CI, 1.42 to 7.78, P ¼ .006), respectively, for relapse. These ﬁndings indicate that the number of
induction courses required to achieve morphological remission in AML adds prognostic information for post-
HCT outcome that is independent of other prognostic factors.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
For many patients with acute myeloid leukemia (AML) in
ﬁrst remission, allogeneic hematopoietic cell transplantation
(HCT) is an effective consolidation therapy. Still, even in theabsence of morphologically detectable disease at the time of
transplantation, relapse remains a major cause of treatment
failure [1,2], although it is widely appreciated that the risk of
disease recurrence varies considerablyamongpatients.Hence,
there has been interest in understanding pretransplantation
factors that could serve as predictors of adverse post-HCT
outcome to inform patients accurately about likely treatment
outcomes and to develop risk-stratiﬁed transplantation
regimens.
Recent attention has focused on the role of pre-
transplantation minimal residual disease (MRD) as indicator
of increased risk of relapse after allogeneic HCT for patients
